Not a good buy right now for an impatient investor: price is below the pivot (9.562) with a negatively expanding MACD, and pattern-based odds favor further downside over the next week/month.
Options positioning is call-heavy (bullish skew), but that sentiment is not confirmed by price action today (-5.28%) and insider selling has surged.
Best near-term setup would require a quick reclaim of 9.56–9.96; without that, risk of a slide toward 9.17 and 8.93 remains elevated heading into earnings (2026-02-26).
Technical Analysis
Trend/price action: Down day (-5.28%) and trading below the Pivot (9.562) tilts the near-term bias bearish.
MACD: Histogram -0.0403, below zero and expanding negatively → bearish momentum strengthening.
RSI(6): 45.91 → neutral, but not showing an oversold bounce signal.
Moving averages: Converging MAs → no strong trend support; combined with MACD suggests downside pressure can persist.
Key levels:
Support: S1 9.168 then S2 8.925
Resistance: R1 9.955 then R2 10.198
Statistical pattern read-through: Similar-candlestick analysis implies ~60% chance of -0.66% next day, -4.76% next week, -4.87% next month.
on 2026-02-26 after hours could be an upside catalyst if margins/EPS rebound (Street EPS est. 0.18).
Neutral/Negative Catalysts
Momentum is currently bearish: MACD is negative and expanding, and price is below the pivot level.
Insider activity: Insiders are selling, with selling amount up 156.20% over the last month.
Profitability deterioration in the latest reported quarter (2025/Q3): net income, EPS, and gross margin all fell sharply YoY.
No supportive news flow in the last week to counter the bearish tape.
Near-term downside risk remains to 9.17 and 8.93 if buyers do not reclaim 9.56 quickly.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 155.431M, up +42.31% YoY (strong top-line growth).
Net income: 7.115M, down -128.03% YoY (major profitability compression).
EPS: 0.10, down -128.57% YoY.
Gross margin: 17.13, down -335.63% YoY (margin pressure is the core issue).
Takeaway: Growth is strong, but the quality of earnings/margins worsened materially—until that trend stabilizes, dips can keep getting bought less aggressively.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating changes or price target updates were provided in the dataset, so the recent Wall Street trend cannot be confirmed.
Wall Street “pro” view (inferred from fundamentals): strong revenue growth and cyclical/earnings upside optionality into the next print.
Wall Street “con” view (inferred from fundamentals/behavioral signals): sharply weaker margins/EPS and increased insider selling reduce confidence in a near-term turnaround.
Wall Street analysts forecast LXU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXU is 9.88 USD with a low forecast of 9.75 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast LXU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXU is 9.88 USD with a low forecast of 9.75 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 9.340
Low
9.75
Averages
9.88
High
10
Current: 9.340
Low
9.75
Averages
9.88
High
10
UBS
Neutral
maintain
AI Analysis
2025-10-30
Reason
UBS
Price Target
AI Analysis
2025-10-30
maintain
Neutral
Reason
UBS raised the firm's price target on LSB Industries to $9.50 from $9.25 and keeps a Neutral rating on the shares.
UBS
Buy
to
Neutral
downgrade
$9.25
2025-07-23
Reason
UBS
Price Target
$9.25
2025-07-23
downgrade
Buy
to
Neutral
Reason
UBS downgraded LSB Industries to Neutral from Buy with a $9.25 price target. Following the 65% increase from the April lows, and 11% year-to-date advance, the firm views the stock as fairly valued, the analyst tells investors. The firm is shifting its preference in the space as it sees a broad based improvement in the outlook for fertilizer pricing, adding that it sees less scope for further improvement in nitrogen.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LXU
